{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T05:01:04Z","timestamp":1789275664054,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-026-26844-0","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:33:52Z","timestamp":1772706832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of a National Volume-Based Procurement Policy in China on purchase of nucleoside\/nucleotide analog drugs for the treatment of chronic hepatitis B virus infection"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross-Degnan","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"26844_CR1","unstructured":"WHO, Hepatitis, B . 2023. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"key":"26844_CR2","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf?sequence=1&isAllowed=y. Accessed 25 August 2021."},{"key":"26844_CR3","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1080\/21645515.2020.1847951","volume":"17","author":"X Zhao","year":"2021","unstructured":"Zhao X, Shi X, Lv M, Yuan B, Wu J. Prevalence and Factors Associated with Hepatitis B Virus Infection Among Household Members: A Cross-Sectional Study in Beijing. Hum Vaccines Immunother. 2021;17:1818\u201324.","journal-title":"Hum Vaccines Immunother"},{"key":"26844_CR4","doi-asserted-by":"publisher","first-page":"718013","DOI":"10.3389\/fpubh.2021.718013","volume":"9","author":"X Wen","year":"2021","unstructured":"Wen X, Yin S, Cui L, Mao L, Lin Z, Yaermaimaiti Z, et al. The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis. Front Public Health. 2021;9:718013.","journal-title":"Front Public Health"},{"key":"26844_CR5","doi-asserted-by":"crossref","unstructured":"Dai Z, Wong IOL, Xie C, Xu W, Xiang Y, Peng L et al. Cost-Effectiveness Analysis of First-Line Treatment for Chronic Hepatitis B in China. Clin Microbiol Infect. 2022;28:300.e1-300.e8.","DOI":"10.1016\/j.cmi.2021.06.024"},{"key":"26844_CR6","first-page":"1420","volume":"38","author":"W Zhou","year":"2022","unstructured":"Zhou W, Huang J, Pan F. Research Progress in Epidemiological Characteristics and Therapeutic Drugs of Chronic Hepatitis B. J Chang Univ Chin. 2022;38:1420\u20134.","journal-title":"J Chang Univ Chin"},{"key":"26844_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2471\/BLT.18.219469","volume":"97","author":"J Liu","year":"2019","unstructured":"Liu J, Liang W, Jing W, Liu M. Countdown to 2030: Eliminating Hepatitis B Disease, China. Bull World Health Organ. 2019;97:230\u20138.","journal-title":"Bull World Health Organ"},{"key":"26844_CR8","doi-asserted-by":"publisher","first-page":"e109652","DOI":"10.1371\/journal.pone.0109652","volume":"9","author":"Q Qiu","year":"2014","unstructured":"Qiu Q, Li Y, Duan X, Yang L, Chen Y, Li H, et al. Impact of a New Reimbursement Program on Hepatitis B Antiviral Medication Cost and Utilization in Beijing, China. PLoS ONE. 2014;9:e109652.","journal-title":"PLoS ONE"},{"key":"26844_CR9","first-page":"457","volume":"26","author":"H You","year":"2023","unstructured":"You H, Wang F, Li T, Sun Y, Xu X, Jia J, et al. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022). J Pract Hepatol. 2023;26:457\u201378.","journal-title":"J Pract Hepatol"},{"issue":"Suppl 1","key":"26844_CR10","first-page":"115","volume":"38","author":"M Subic","year":"2018","unstructured":"Subic M, Zoulim F. How to Improve Access to Therapy in Hepatitis B Patients. Liver Int Off J Int Assoc Study Liver. 2018;38(Suppl 1):115\u201321.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"26844_CR11","first-page":"36","volume":"14","author":"L Sheng","year":"2019","unstructured":"Sheng L, Li X, Hu X. Application of Nucleoside Anti-Hepatitis B Drugs Based on 4\u2009+\u20097 Quantified Purchasing. China J Pharm Econ. 2019;14:36\u20139.","journal-title":"China J Pharm Econ"},{"issue":"3","key":"26844_CR12","first-page":"197","volume":"2","author":"LG Lu","year":"2014","unstructured":"Lu LG. Antiviral therapy of liver cirrhosis related to hepatitis B virus infection. J Clin Translational Hepatol. 2014;2(3):197.","journal-title":"J Clin Translational Hepatol"},{"issue":"2","key":"26844_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/0020731421997094","volume":"51","author":"MA Rodwin","year":"2021","unstructured":"Rodwin MA. How the United Kingdom controls pharmaceutical prices and spending: learning from its experience. Int J Health Serv. 2021;51(2):229\u201337.","journal-title":"Int J Health Serv"},{"issue":"1","key":"26844_CR14","doi-asserted-by":"publisher","first-page":"1601060","DOI":"10.1080\/20016689.2019.1601060","volume":"7","author":"NR Verghese","year":"2019","unstructured":"Verghese NR, Barrenetxea J, Bhargava Y, Agrawal S, Finkelstein EA. Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview. J market access health policy. 2019;7(1):1601060.","journal-title":"J market access health policy"},{"issue":"3","key":"26844_CR15","first-page":"789","volume":"24","author":"BL Weinstein","year":"2006","unstructured":"Weinstein BL. The role of group purchasing organizations (GPOs) in the US medical industry supply chain. Estudios De Economia Aplicada. 2006;24(3):789\u2013801.","journal-title":"Estudios De Economia Aplicada"},{"key":"26844_CR16","doi-asserted-by":"publisher","first-page":"984794","DOI":"10.3389\/fphar.2023.984794","volume":"14","author":"X Wen","year":"2023","unstructured":"Wen X, Xu L, Chen X, Wu R, Luo J, Wan Y, Mao Z. A quasi-experimental study of the volume-based procurement (VBP) effect on antiviral medications of hepatitis B virus in China. Front Pharmacol. 2023;14:984794. https:\/\/doi.org\/10.3389\/fphar.2023.984794.","journal-title":"Front Pharmacol"},{"key":"26844_CR17","doi-asserted-by":"publisher","first-page":"842944","DOI":"10.3389\/fphar.2022.842944","volume":"13","author":"J Yuan","year":"2022","unstructured":"Yuan J, Lu ZK, Xiong X, Lee T-Y, Huang H, Jiang B. Impact of National Volume-Based Procurement on the Procurement Volumes and Spending for Antiviral Medications of Hepatitis B Virus. Front Pharmacol. 2022;13:842944.","journal-title":"Front Pharmacol"},{"key":"26844_CR18","first-page":"169","volume":"33","author":"L Yang","year":"2021","unstructured":"Yang L, Cai L. Trend of Nucleoside\/Nucleotide Antiviral Drugs in the Treatment of Chronic Hepatitis B. Strait Pharm J. 2021;33:169\u201372.","journal-title":"Strait Pharm J"},{"key":"26844_CR19","unstructured":"National Bureau of Statistics. China Statistical Yearbook . 2023 [cited 2023 Jun 15]. Available from: http:\/\/www.stats.gov.cn\/sj\/ndsj\/"},{"key":"26844_CR20","unstructured":"WHO Collaborating Center for Drug statistics Methodology. WHOCC-ATC\/DDD Index. Available from: https:\/\/www.whocc.no\/atc_ddd_index\/"},{"key":"26844_CR21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/14737167.2021.1908890","volume":"22","author":"K-B Son","year":"2022","unstructured":"Son K-B. Understanding Long-Listed Pharmaceutical Products Without Competition in South Korea: Policy Implications in Managing Generic Entrants and Pharmaceutical Expenditures. Expert Rev Pharmacoecon Outcomes Res. 2022;22:815\u201322.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"26844_CR22","doi-asserted-by":"publisher","first-page":"e0327298","DOI":"10.1371\/journal.pone.0327298","volume":"20","author":"Y Lin","year":"2025","unstructured":"Lin Y, Lin X, Xia R, Chen J, Lin Z, Lu S. Tenofovir alafenamide is superior to tenofovir disoproxil fumarate and entecavir in cost-effectiveness of treatment of chronic hepatitis B in china with new volume-based procurement policy. PLoS ONE. 2025;20(7):e0327298.","journal-title":"PLoS ONE"},{"key":"26844_CR23","unstructured":"Biden-Harris Administration Moves Forward with Medicare Drug Price Negotiations to Lower Prescription Drug Costs for People with Medicare. Available from: https:\/\/www.hhs.gov\/about\/news\/2023\/10\/03\/biden-harris-administration-moves-medicare-drug-price-negotiations-lower-prescription-drug-costs-people-medicare.html"},{"key":"26844_CR24","unstructured":"Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Chin J Hepatol. 2015;23(12):888\u2013905."},{"key":"26844_CR25","first-page":"938","volume":"27","author":"Chinese Medical Association Chinese Society of Infectious Diseases, Chinese Medical Association Chinese Society of Hepatology","year":"2019","unstructured":"Chinese Medical Association Chinese Society of Infectious Diseases, Chinese Medical Association Chinese Society of Hepatology. The Guidelines of Prevention and Treatment for Chronic Hepatitis B (2019 Version). Chin J Hepatol. 2019;27:938\u201361.","journal-title":"Chin J Hepatol"},{"issue":"2","key":"26844_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000444990","volume":"32","author":"C Roderburg","year":"2016","unstructured":"Roderburg C, Tacke F, Trautwein C. Antiviral therapy in patients with viral hepatitis and hepatocellular carcinoma: indications and prognosis. Visc Med. 2016;32(2):121\u20136.","journal-title":"Visc Med"},{"key":"26844_CR27","unstructured":"Winnie F, Benjamin O, Jiandong S, Kwong N. Effect of drug subsidy policy on empagliflozin utilisation in Singapore: An interrupted time series analysis.https:\/\/www.asianpharmacoepi.org\/wp-content\/uploads\/2022\/12\/ACPE13-ePoster-abstracts.pdf"},{"issue":"1","key":"26844_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.vhri.2013.02.002","volume":"2","author":"L Wei","year":"2013","unstructured":"Wei L, Hu S, Hou J, Liu G, Ren H, Duan Z, Jia J. A novel estimation of the impact of treatment with entecavir on long-term mortality, morbidity, and health care costs of chronic hepatitis B in China. Value health Reg issues. 2013;2(1):48\u201356.","journal-title":"Value health Reg issues"},{"key":"26844_CR29","doi-asserted-by":"publisher","first-page":"420","DOI":"10.14218\/JCTH.2022.00167","volume":"10","author":"X Zhao","year":"2022","unstructured":"Zhao X, Li M, Wang H, Xu X, Wu X, Sun Y, et al. Impact of National Volume-Based Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China. J Clin Transl Hepatol. 2022;10:420\u20138.","journal-title":"J Clin Transl Hepatol"},{"key":"26844_CR30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/1751-2980.12794","volume":"20","author":"M Li","year":"2019","unstructured":"Li M, Kong YY, Wu SS, Zhou JL, Wu XN, Wang L, et al. Impact of Reimbursement Program on Liver-Related Mortality in Patients with Chronic Hepatitis B in Beijing, China. J Dig Dis. 2019;20:467\u201375.","journal-title":"J Dig Dis"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-026-26844-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-26844-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-26844-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:52:54Z","timestamp":1776077574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-026-26844-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["26844"],"URL":"https:\/\/doi.org\/10.1186\/s12889-026-26844-0","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study has been submitted to the Ethics Committee of Peking University for review and approval. The investigation and research process conforms to the principles outlined in the Helsinki Declaration. This study uses medical institution procurement records, which do not involve patient or personal information, and therefore are exempt from informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This study uses medical institution procurement records, which do not involve patient or personal information, and therefore are exempt from informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1200"}}